Ensysce Biosciences
ENSC
12 hedge funds and large institutions have $231K invested in Ensysce Biosciences in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
33% more funds holding
Funds holding: 9 → 12 (+3)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1.66% less ownership
Funds ownership: 2.05% → 0.39% (-1.7%)
68% less capital invested
Capital invested by funds: $714K → $231K (-$483K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$36.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$31.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$27.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$284 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$114 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$426K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$65.3K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $134K | -$426K | -15,022 | -70% |
|
|
2
Citadel Advisors
Miami,
Florida
| $26.2K | +$36.2K | +1,274 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $22.5K | +$31.1K | +1,095 | New |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $21.3K | – | – | – |
|
|
TSS
5
Two Sigma Securities
New York
| $20.2K | +$27.6K | +974 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $5.42K | +$57 | +2 | +0.8% |
|
7
BlackRock
New York
| $1.35K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $203 | +$284 | +10 | New |
|
|
9
Bank of America
Charlotte,
North Carolina
| $81 | +$114 | +4 | New |
|
10
Wells Fargo
San Francisco,
California
| $29 | – | – | – |
|
|
PMFA
11
Plante Moran Financial Advisors
Southfield,
Michigan
| $28 | – | – | – |
|
|
WAM
12
Wolverine Asset Management
Chicago,
Illinois
| $16 | – | – | – |
|
|
AFM
13
Anson Funds Management
Dallas,
Texas
| – | -$65.3K | -2,417 | Closed |
|
|
GCP
14
GSA Capital Partners
London,
United Kingdom
| – | -$32K | -1,170 | Closed |
|
ENSC Hedge Fund Activity: Q3 2023 in Review
12 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q3 2023, worth a combined $231K — down 68% from $714K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ENSC positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $36.2K. The largest seller was Sabby Management, cutting an estimated $426K.
- 12 institutional investors held Ensysce Biosciences (ENSC) as of Q3 2023, up from 9 in Q2 2023.
- Funds reported $231K of Ensysce Biosciences stock for Q3 2023, down 68% quarter-over-quarter.
- 5 funds opened new Ensysce Biosciences positions in Q3 2023 and 2 closed out, a net change of +3 holders.
- The largest Ensysce Biosciences buyer in Q3 2023 was Citadel Advisors, an estimated $36.2K added.
- The largest Ensysce Biosciences seller in Q3 2023 was Sabby Management, an estimated $426K sold.
Based on aggregated 13F filings for Q3 2023.